Vaccine Development, Clinical Trials, and International Collaborations to Fight the Pandemic: Coronavirus Disease-2019
DOI:
https://doi.org/10.17140/ctpoj.2024.v7.i01.pp16-21.2281Keywords:
Pandemic, Immunogen, Adenovirus, Vaccines, Clinical trials, Global partnershipsAbstract
The advent of coronavirus disease-2019 (COVID-19), in March 2020, has forced the entire world into continuously changing dimensions, the emergence of variants has put forward a challenge to scientists and doctors, indeed the entire world to cope with it. A lot of clinical research was done, starting with the use of Chloroquine, an anti-malarial drug to treat COVID-19, antivirals and indeed entire world experienced havoc and a death toll due to the coronavirus which led to the emergence of various vaccine platforms developed against changing variants of coronavirus and in this pandemic messenger Ribonucleic acid (mRNA) and nanotechnology added new dimensions to vaccine development. Vaccines may induce additional cellular or humoral immune regulations, including The cell (helper T-cell) responses and germinal center responses, and form relevant memory cells, which in turn enhance their efficiency. As the benefit outweighs the safety issues with vaccination so far, the World Health Organization (WHO), has approved a total of ten vaccines, to use in emergencies, including 3 Indian vaccines (Covovax™, Covaxin® and Sputnik V). The first part, of this mini-review highlights vaccine production, and the clinical trials landscape, and the second part discusses the emergence of global partnerships, and the equity of vaccines to all, taken together, combating pandemics.
References
Khandker SS, Godman B, Md. Irfan Jawad, et al. A systematic review on COVID-19 vaccine strategies, their effectiveness, and is-sues. Vaccines (Basel). 2021; 9: 1387. doi: 10.3390/vaccines9121387
Rangraze IR, Khan SS, Sayyad Y. Coronavirus disease-2019 vac-cines and the vaccination challenges in India: A review. Intern Med Open J. 2021; 5(1): 6-13. doi: 10.17140/IMOJ-5-117
Chakraborty C, Sharma AR, Bhattacharya M, Lee S-S. From COVID-19 to cancer mRNA vaccines: Moving from bench to clin-ic in the vaccine landscape. Front Immunol. 2021; 12: 679344. doi: 10.3389/fimmu.2021.679344
Li M, Wang H, Tian L, et al. COVID-19 vaccine development: milestones, lessons, and prospects COVID-19 vaccine develop-ment: milestones, lessons and prospects. Signal Transduct Target Ther. 2022; 7(1): 146. doi: 10.1038/s41392-022-00996-y
Motamedia H, Ari MM, Dashtbin S, et al. An updated review of globally reported SARS-CoV-2 vaccines in preclinical and clin-ical stages. Int Immunopharmacol. 2021; 96: 107763. doi: 10.1016/j. intimp.2021.107763
World Health Organization (WHO). WHO recommendation Bharat Biotech International Ltd – COVID-19 vaccine (Whole Vi-rion Inactivated Corona Virus. https://extranet.who.int/pqweb/ vaccines/who-recommendation-bharat-biotech-internation-al-ltd-covid-19-vaccine-whole-virion. Accessed May 18, 2022.
COVAXIN®. Summary of Product Characteristics (SmPC). https://www.bharatbiotech.com/images/covaxin/covaxin-smpc. pdf. Accessed May 18, 2022.
Ella R, Vadrevu KM, Jogdand H, et al. Safety and immuno-genicity of an inactivated SARS-CoV-2 vaccine, BBV152: A dou-ble-blind, randomized, phase 1 trial. Lancet Infect Dis. 2021; 21: 637- 646. doi: 10.1016/S1473-3099(20)30942-7
Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomized, double-blind, con-trolled, phase 3 trial. Lancet. 2021; 398(10317): 2173-2184. doi:
1016/S0140-6736(21)02000-6 10. COVAXIN®. Whole Virion Inactivated Coronavirus (SARS-CoV-2) Vaccine. https://www.bharatbiotech.com/images/covax-in/covaxin-pack-insert.pdf. Accessed May 18, 2022.
COVISHIELD™. Summary of Product Characteristics (SmPC). Malekar P https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/en/ Smpcserum.pdf. Accessed May 18, 2022.
COVOVAX™. SARS-CoV-2 rS Protein (COVID-19) recom-binant spike protein Nanoparticle VaccineCOVOVAX™. https:// www.seruminstitute.com/COVOVAX.php. Accessed May 18, 2022.
Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021; 385: 1172- 1183. doi: 10.1056/NEJMoa2107659
CORBEVAX™. Summary of Product Characteristics (SmPC). https://cdsco.gov.in/opencms/resources/UploadCD-SCOWeb/2018/UploadSmPC/ebio.pdf. Accessed May 18, 2022.
SPUTNIK V. Summary of Product Characteristics (SmPC). https://cdsco.g ov.in/opencms/resources/UploadCD-SCOWeb/2018/UploadSmPC/SMPCsputinikdr.Reddys.pdf. Ac-cessed May 18, 2022.
Sputnik V. COVID-19 vaccine candidate appears safe and ef-fective. Lancet. 2021; 397(10275): 642-643. doi: 10.1016/S0140- 6736(21)00191-4
Momina T, Kansagraa K, Patel H, et al. Safety and immuno-genicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clini-cal study by intradermal route in healthy subjects in India. EClin-icalMedicine. 2021; 38: 101020. doi: 10.1016/j.eclinm.2021.101020
Department of Biotechnology, Ministry of Science & Tech-nology. https://dbtindia.gov.in/pressrelease/department-biotech-nology-provides-seed-funding-gennova-biopharmaceuticals-lt-d%E2%80%99s-novel. Accessed May 18, 2022.
Clinical Trial Registry of India (CTRI). Total Number of Trials Registered in CTRI: 42952. http://ctri.nic.in/Clinicaltrials/ login.php. Accessed May 18, 2022.
COWIN. https://dashboard.cowin.gov.in/. Accessed May 18, 2022.
World Health Organization (WHO). This Dashboard Sum-marizes Officially Reported COVID-19 Vaccination Data. https://app.powerbi.com/view?r=eyJrIjoiMWNjNzZkNjctZ-TNiNy00YmMzLTkxZjQtNmJiZDM2MTYxNzEwIiwidCI6I-mY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGF-mYjU5MCIsImMiOjh9. Accessed May 18, 2022.
Coalition for Epidemic Preparedness Innovations (CEPI). CEPI, THSTI and Panacea Biotec partner to develop broadly pro-tective Betacoronavirus vaccines. https://cepi.net/news_cepi/ cepi-thsti-and-panacea-biotec-partner-to-develop-broadly-protec-tive-betacoronavirus-vaccines/. Accessed May 18, 2022.
Coalition for Epidemic Preparedness Innovations (CEPI). The urgency of now. https://endpandemics.cepi.net/. Accessed May 18, 2022.
Saville M, Cramer JP, Downham M, et al. Delivering pandemic vaccines in 100-days-what will it take? . [In: Online ahead of print]. N Engl J Med. 2022. doi: 10.1056/NEJMp2202669
World Health Organization (WHO). Context: First year of the act-accelerator and evolving focus. 2022.
Altindis E. Inequitable COVID-19 vaccine distribution and the Submit your article to this journal | https://openventio.org/submit-manuscript/ intellectual property rights prolong the pandemic. Expert Review of Vaccines.2021;21(4):427-430.doi:10.1080/14760584.2022.2014819
Sharun K, Dhama K. India’s role in COVID-19 vaccine diplo-macy. J Travel Med. 2021; 28: taab064. doi: 10.1093/jtm/taab064
Data Futures Platform. Global dashboard for vaccine equity. https://data.undp.org/vaccine-equity/. Accessed May 18, 2022.
Acharya KP, Ghimire TR, Subramanya SH. Access to and equi-table distribution of the COVID-19 vaccine in low-income coun-tries. NPJ Vaccines. 2021; 6: 54. doi: 10.1038/s41541-021-00323-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Clinical Trials and Practice – Open Journal (CTP) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
